Literature DB >> 2215854

Effects of acute and subacute cocaine administration on the CNS dopaminergic system in Wistar-Kyoto and spontaneously hypertensive rats: III. Dopamine uptake.

D K Lim1, Z J Yu, B Hoskins, R W Rockhold, I K Ho.   

Abstract

The characteristics of dopamine uptake after acute and subacute cocaine administration were determined in striata from WKY and SHR. In acutely-treated (40 mg/kg, s.c.) rats, significant increases in the Vmax of dopamine uptake were observed 30 min after the cocaine injection in both strains, without changes in Km values. The in vitro IC50 for cocaine was significantly decreased at 30 min in WKY and at 2 h in SHR. However, the in vitro IC50 for GBR-12909 was significantly increased at 30 min and at 2 h in both strains following cocaine administration. In both strains, the density (Bmax) of the [3H]GBR-12935 binding site was significantly increased at 30 min and at 2 h with no changes in Kd. In subacutely-treated (20 mg/kg, twice daily for 3 or 7 days) rats, a significant increase in the Km for dopamine uptake was observed in 7 day treated SHR. The in vitro IC50 for GBR-12909 was significantly increased in 3 day treated WKY. The results suggest that cocaine administration alters dopamine uptake and characteristics of dopamine uptake sites in the rat brain.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2215854     DOI: 10.1007/bf00973754

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  30 in total

1.  Neostriatal dopamine uptake and reversal of age-related movement disorders with dopamine-uptake inhibitors.

Authors:  C A Altar; J F Marshall
Journal:  Ann N Y Acad Sci       Date:  1988       Impact factor: 5.691

2.  Extracellular cocaine and dopamine concentrations are linearly related in rat striatum.

Authors:  L C Nicolaysen; H T Pan; J B Justice
Journal:  Brain Res       Date:  1988-07-26       Impact factor: 3.252

3.  Brain dopamine depletion by lesions in the substantia nigra attenuates the development of hypertension in the spontaneously hypertensive rat.

Authors:  M van den Buuse; D H Versteeg; W de Jong
Journal:  Brain Res       Date:  1986-03-12       Impact factor: 3.252

4.  Differential effects of dopaminergic drugs on open-field behavior of spontaneously hypertensive rats and normotensive Wistar-Kyoto rats.

Authors:  M van den Buuse; W de Jong
Journal:  J Pharmacol Exp Ther       Date:  1989-03       Impact factor: 4.030

5.  Sodium-sensitive cocaine binding to rat striatal membrane: possible relationship to dopamine uptake sites.

Authors:  L T Kennedy; I Hanbauer
Journal:  J Neurochem       Date:  1983-07       Impact factor: 5.372

6.  Dopamine uptake is differentially regulated in rat striatum and nucleus accumbens.

Authors:  C Missale; L Castelletti; S Govoni; P F Spano; M Trabucchi; I Hanbauer
Journal:  J Neurochem       Date:  1985-07       Impact factor: 5.372

7.  Biochemical and pharmacological characterization of [3H]GBR 12935 binding in vitro to rat striatal membranes: labeling of the dopamine uptake complex.

Authors:  P H Andersen
Journal:  J Neurochem       Date:  1987-06       Impact factor: 5.372

8.  Reduction of dopamine uptake and cocaine binding in mouse striatum by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

Authors:  H Sershen; M E Reith; A Hashim; A Lajtha
Journal:  Eur J Pharmacol       Date:  1984-06-15       Impact factor: 4.432

9.  The role of dopamine in the regulation of neurotransmitter release in spontaneously hypertensive rats.

Authors:  K Tsuda; S Tsuda; Y Masuyama
Journal:  Jpn Heart J       Date:  1988-03

10.  Central dopaminergic neurons during development of genetic and DOCA-salt hypertension in the rat.

Authors:  G Le Fur; F Guilloux; M Kabouche; N Mitrani; O Ferris; A Uzan
Journal:  Brain Res       Date:  1981-04       Impact factor: 3.252

View more
  1 in total

1.  Dopaminergic Modulation of Goal-Directed Behavior in a Rodent Model of Attention-Deficit/Hyperactivity Disorder.

Authors:  Joman Y Natsheh; Michael W Shiflett
Journal:  Front Integr Neurosci       Date:  2018-10-05
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.